| Generic name | Vorinostat |
| Pronunciation | voh-RIN-oh-stat |
| Brand name(s), other common name(s) | Zolinza® |
| Drug type | Histone deacetylase inhibitor |
| How the drug is given | By mouth |
Indications and Usage
Vorinostat is FDA approved to treat cutaneous T-cell lymphoma (CTCL) in patients whose CTCL gets worse, does not go away or comes back after treatment with two systemic therapies.
Side effects needing medical attention
Blood clots in the legs (deep vein thrombosis); sudden swelling in a leg; pain or tenderness in the leg (the pain may only be felt when standing or walking); increased warmth in the area where the swelling is; skin redness or change in skin color; sudden, sharp chest pain; rapid pulse; fainting; cough with bloody secretions; feeling anxious; sweating; dehydration (loss of too much fluid from the body); low red blood cells; unusual bleeding or bruising under the skin; high blood sugar; paleness, shortness of breath and unusual tiredness.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.